137 related articles for article (PubMed ID: 9894455)
1. Low-stage carcinoma of the male breast. A histologic, immunohistochemical, and flow cytometric comparison with localized female breast carcinoma.
Wick MR; Sayadi H; Ritter JH; Hill DA; Reddy VB; Gattuso P
Am J Clin Pathol; 1999 Jan; 111(1):59-69. PubMed ID: 9894455
[TBL] [Abstract][Full Text] [Related]
2. Hormone Receptor-Positive Breast Cancer Has a Worse Prognosis in Male Than in Female Patients.
Li X; Yang J; Krishnamurti U; Huo L; Ward KC; O'Regan R; Peng L
Clin Breast Cancer; 2017 Aug; 17(5):356-366. PubMed ID: 28576631
[TBL] [Abstract][Full Text] [Related]
3. Men and women show similar survival outcome in stage IV breast cancer.
Wu SG; Zhang WW; Liao XL; Sun JY; Li FY; Su JJ; He ZY
Breast; 2017 Aug; 34():115-121. PubMed ID: 28577471
[TBL] [Abstract][Full Text] [Related]
4. Overall Survival of Men and Women With Breast Cancer According to Tumor Subtype: A Population-based Study.
Leone J; Zwenger AO; Leone BA; Vallejo CT; Leone JP
Am J Clin Oncol; 2019 Feb; 42(2):215-220. PubMed ID: 30499840
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
[TBL] [Abstract][Full Text] [Related]
6. Male and female breast cancer--differences in DNA ploidy, p21 and p53 expression reinforce the possibility of distinct pathways of oncogenesis.
André S; Pinto AE; Laranjeira C; Quaresma M; Soares J
Pathobiology; 2007; 74(6):323-7. PubMed ID: 18087196
[TBL] [Abstract][Full Text] [Related]
7. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases.
Wang-Rodriguez J; Cross K; Gallagher S; Djahanban M; Armstrong JM; Wiedner N; Shapiro DH
Mod Pathol; 2002 Aug; 15(8):853-61. PubMed ID: 12181271
[TBL] [Abstract][Full Text] [Related]
8. Poor prognosis of male triple-positive breast Cancer patients: a propensity score matched SEER analysis and molecular portraits.
Wang B; Wang H; Zhao A; Zhang M; Yang J
BMC Cancer; 2021 May; 21(1):523. PubMed ID: 33964913
[TBL] [Abstract][Full Text] [Related]
9. Bcl-2 expression in male breast carcinoma.
Pich A; Margaria E; Chiusa L
Virchows Arch; 1998 Sep; 433(3):229-35. PubMed ID: 9769126
[TBL] [Abstract][Full Text] [Related]
10. Male breast cancer in the veterans affairs population: a comparative analysis.
Nahleh ZA; Srikantiah R; Safa M; Jazieh AR; Muhleman A; Komrokji R
Cancer; 2007 Apr; 109(8):1471-7. PubMed ID: 17342768
[TBL] [Abstract][Full Text] [Related]
11. [Analysis on the clinical and prognostic features of 71 male patients with breast cancer].
Liu DY; Xie GR; Chen M
Zhonghua Liu Xing Bing Xue Za Zhi; 2013 Feb; 34(2):187-90. PubMed ID: 23751479
[TBL] [Abstract][Full Text] [Related]
12. Molecular subtyping of male breast cancer using alternative definitions and its prognostic impact.
Nilsson C; Johansson I; Ahlin C; Thorstenson S; Amini RM; Holmqvist M; Bergkvist L; Hedenfalk I; Fjällskog ML
Acta Oncol; 2013 Jan; 52(1):102-9. PubMed ID: 22928693
[TBL] [Abstract][Full Text] [Related]
13. Cytometric DNA analysis and prognostic biomarkers in breast carcinoma. Expression of P53 product in the different ploidy classes.
Leonardi E; Cristofori A; Caffo O; Dalla Palma P
Anal Cell Pathol; 1997; 15(1):31-45. PubMed ID: 9373711
[TBL] [Abstract][Full Text] [Related]
14. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer.
Barbareschi M; Leonardi E; Mauri FA; Serio G; Dalla Palma P
Am J Clin Pathol; 1992 Oct; 98(4):408-18. PubMed ID: 1357956
[TBL] [Abstract][Full Text] [Related]
15. Lack of relationship between the expression of Hsp27 heat shock estrogen receptor-associated protein and estrogen receptor or progesterone receptor status in male breast carcinoma.
Muñoz de Toro MM; Luque EH
J Steroid Biochem Mol Biol; 1997 Mar; 60(5-6):277-84. PubMed ID: 9219918
[TBL] [Abstract][Full Text] [Related]
16. Matched-pair analysis of patients with female and male breast cancer: a comparative analysis.
Foerster R; Foerster FG; Wulff V; Schubotz B; Baaske D; Wolfgarten M; Kuhn WC; Rudlowski C
BMC Cancer; 2011 Aug; 11():335. PubMed ID: 21816051
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic characteristics and survival of male breast cancer.
Liu D; Xie G; Chen M
Int J Clin Oncol; 2014 Apr; 19(2):280-7. PubMed ID: 23640121
[TBL] [Abstract][Full Text] [Related]
18. Comparative study of two androgen-induced markers (apolipoprotein D and pepsinogen C) in female and male breast carcinoma.
Serra C; Vizoso F; Lamelas ML; Rodríguez JC; González LO; Merino AM; Baltasar A; Pérez-Vázquez MT; Medrano J
Int J Surg Investig; 2000; 2(3):183-92. PubMed ID: 12678518
[TBL] [Abstract][Full Text] [Related]
19. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
[TBL] [Abstract][Full Text] [Related]
20. Chinese female breast cancer patients show a better overall survival than their male counterparts.
Xia LP; Zhou FF; Guo GF; Wang F; Wang X; Yuan ZY; Zhang B
Chin Med J (Engl); 2010 Sep; 123(17):2347-52. PubMed ID: 21034547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
